GlassScriptPhysician profile
Mel K Strange
NPI 1144299603
$8,067.76
in general payments reported to CMS, 2019-2025
37 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $1,394 · 2021: $2,044 · 2022: $242 · 2023: $967 · 2024: $1,352 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,836.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,298.55 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $912.81 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $780.05 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $717.01 | 2019-2025 | |
| Novo Nordisk INC | $686.87 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $452.95 | 2019-2025 | Jardiance, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $391.11 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $390.49 | 2021-2025 | |
| Abbvie INC. | $376.87 | 2021-2023 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $322.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $209.20 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $207.48 | 2019-2021 | |
| Astellas Pharma US INC | $153.57 | 2019-2021 | |
| Allergan, INC. | $141.63 | 2019-2020 | |
| Mylan Specialty L.P. | $114.11 | 2019-2023 | Yupelri |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mel Strange listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.